Ellington Management Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ellington Management Group’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-12,800	Closed	-$192K	–	794
2017 Q3	$192K	Sell	12,800 -17,900	-58%	-$198K	0.03%	536
2017 Q2	$270K	Buy	30,700 +17,000	+124%	+$109K	0.04%	439
2017 Q1	$71K	Buy	+13,700	New	+$55K	﹤0.01%	649
2016 Q4	–	Sell	-17,000	Closed	-$79K	–	775
2016 Q3	$79K	Buy	17,000 +1,900	+13%	+$9.66K	0.02%	621
2016 Q2	$87K	Sell	15,100 -23,800	-61%	-$152K	0.12%	221
2016 Q1	$235K	Buy	+38,900	New	+$234K	0.1%	313
2015 Q2	–	Sell	-45,900	Closed	-$720K	–	858
2015 Q1	$720K	Buy	+45,900	New	+$710K	0.15%	183
2014 Q3	–	Sell	-37,000	Closed	-$565K	–	455
2014 Q2	$565K	Buy	+37,000	New	+$532K	0.26%	86

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ellington Management Group's SGMO Position: Q4 2017 in Review

Ellington Management Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2017, closing a stake of 12,800 shares — an estimated $192K sold.

Ellington Management Group first reported a position in SGMO in Q2 2014 and held it in 8 quarters. The position peaked at $720K in Q1 2015. 170 funds tracked by Wall St. Rank hold SGMO as of Q4 2017.

Ellington Management Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2017 after selling out during the quarter.
Ellington Management Group sold 12,800 SANGAMO THERAPEUTICS INC shares in Q4 2017, an estimated $192K.
Ellington Management Group first reported a position in SANGAMO THERAPEUTICS INC in Q2 2014 and held it in 8 quarters.
Ellington Management Group's SANGAMO THERAPEUTICS INC position peaked at $720K in Q1 2015.
170 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2017.

Based on Ellington Management Group's 13F filing for Q4 2017, filed 14 Feb 2018.